Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingrui He

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry|October 14, 2022
Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocyclesXiang Qi, Songwei Jiang, Zi Hui, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2023
Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic targetJunzhi Zhou, Xiaohe Ma, Xingrui He, et al.
Chemmedchem|May 1, 2023
Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3-d]pyrimidine and Pyrrolo[2,3-b]pyridine ScaffoldsNian-Dong Mao, Yuan Gao, Xia-Wen Dang, et al.
Biochemical Pharmacology|July 14, 2025
A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phaseChen-Chen Wang, Jilong Duan, Nian-Dong Mao, et al.
Cell Death & Disease|May 18, 2026
Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancerMaría Jimena Abrey-Recalde, Flavie Mialhe, Thi Khanh Le, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry|October 14, 2022
Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocyclesXiang Qi, Songwei Jiang, Zi Hui, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2023
Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic targetJunzhi Zhou, Xiaohe Ma, Xingrui He, et al.
Chemmedchem|May 1, 2023
Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3-d]pyrimidine and Pyrrolo[2,3-b]pyridine ScaffoldsNian-Dong Mao, Yuan Gao, Xia-Wen Dang, et al.
Biochemical Pharmacology|July 14, 2025
A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phaseChen-Chen Wang, Jilong Duan, Nian-Dong Mao, et al.
Cell Death & Disease|May 18, 2026
Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancerMaría Jimena Abrey-Recalde, Flavie Mialhe, Thi Khanh Le, et al.
Pageof 3